Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 79 of 102, showing 5 Applications out of 508 total, starting on record 391, ending on 395

# Protocol No Study Title Investigator(s) & Site(s)

391.

ECCT/11/08/03   Compare the Efficacy and Safety of Gentian Violet to that of Nystatin
    A Phase III, Open-Label, Randomized, Assessment-Blinded Clinical Trial to Compare the Safety and Efficacy of Topical Gentian Violet to that of Nystatin Oral Suspension for the Treatment of Oropharyngeal Candidiasis in HIV-1 Infected Participants in Non-U.S. Settings   
Principal Investigator(s)
1. Deborah C Langat
Site(s) in Kenya
1. Kenya Medical Research Institute Walter Reed Project Clinical Research Centre (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
View

392.

ECCT/16/08/02   Zeenk study
    Zeenk Acceptability Study   
Principal Investigator(s)
1. Margaret Oluka
2. David Kimutai
3. Caren Emadu
Site(s) in Kenya
1. Mbagathi District Hospital (Nairobi City county)
2. Mama Lucy Kibaki Hospital (Nairobi City county)
 
View

393.

ECCT/20/02/01   Pharm PrEP for AGYW
    Pilot evaluation of pharmacy-based pre-exposure prophylaxis (PrEP) delivery   
Principal Investigator(s)
1. Prof. Elizabeth Ann Bukusi
Site(s) in Kenya
KEMRI/CMR/RCTP Kisumu-Lumumba Sub-County Hospital
 
View

394.

ECCT/14/02/03  
    A Phase 1/2 Randomized, Double-Blind, Dose-Finding Study to Assess the Safety, Tolerability, and Immunogenicity of Inactivated  Streptococcus pneumoniae Whole Cell Vaccine Formulated with Alum (PATH-wSP) in Healthy Kenyan Young Adults and PCV-Primed Toddlers (12-15 Months of Age)       
Principal Investigator(s)
1. Nekoye Namungu Otsyula
2. Walter Otieno
Site(s) in Kenya
Kenya Medical Research Institute (KEMRI)/Walter Reed Project, Kombewa Clinical Research Center
 
View

395.

ECCT/20/06/03   CVIA078
    A Phase 2b randomized, open-label, controlled, single center study in Plasmodium falciparum-infected and uninfected adults age 18-55 years old in Kenya to evaluate the efficacy of the delayed, fractional dose RTS,S/AS01E malaria vaccine in subjects treated with artemisinin combination therapy plus primaquine   
Principal Investigator(s)
1. Nathanial Kelsey Copeland
Site(s) in Kenya
Kombewa Clinical Research Centre
 
View